drugset
drugset / Trial / NCT01309425

A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers

NCT01309425 ↗

Phase 1 Completed 52 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to evaluate the dose-proportionality of the pharmacokinetics of tapentadol (CG5503) in healthy Japanese and Korean adult male participants.

Timeline

Start
2011-02
Primary completion
—
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tapentadol Small molecule 25 mg Oral
Subject Tapentadol Small molecule 50 mg Oral
Subject Tapentadol Small molecule 100 mg Oral
Subject Tapentadol Small molecule 200 mg Oral

Indications

No indication recorded.